Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Click here to access webcast replay Core 2022 development initiatives: Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) Initiation and completion in 2H 2022 of investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome with intestinal failure (SBS-IF) FDA conditional approval in December 2021 of Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea (CID) in dogs Fourth quarter 2021 Mytesi net revenue was approximately $2.1 million versus approximately $0.6 million in the third quarter of 2021, an increase of 230% SAN FRANCISCO, CA / ACCESSWIRE / March 14, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the recording of the company's March 14, 2022, investor webcast regarding company updates and reported consolidated financial results for the year ended December 31, 2021 can be accessed by clicking here . About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals, & Napo Therapeutics Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea.

Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast

AnPac Bio-Medical Science Co

Ra Medical Systems Inc

Exela Technologies

Reddit penny stocks under $1 to watch this week. The post 5 Penny Stocks Under $1 To Buy According To Redditors This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks Under $1 To Buy According To Redditors This Week

Core 2022 development initiatives: Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) Initiation and completion in 2H 2022 of investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome with intestinal failure (SBS-IF) FDA conditional approval of Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea (CID) in dogs Fourth quarter 2021 Mytesi net revenue was approximately $2.1 million versus approximately $0.6 million in the third quarter of 2021, an increase of 230% REMINDER: Jaguar to host investor webcast Monday, March 14th at 8:30 a.m. Eastern regarding 2021 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / March 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided company updates and reported consolidated financial results for the year ended December 31, 2021.

Jaguar Health Provides Company Updates and Reports 2021 Financials

Click here to register for webcast Company plans to file its Annual Report on March 11, 2022 on Form 10-K for the fiscal year ended December 31, 2021 SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Monday, March 14, 2022, at 8:30 a.m. Eastern Time to review fourth-quarter 2021 financials and provide corporate updates.

Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates

Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA U.S. veterinarians, veterinary oncologists, and members of the media can click here to register for the CID Treatment Forum SAN FRANCISCO, CA / ACCESSWIRE / March 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company is hosting a treatment forum for veterinarians about chemotherapy-induced diarrhea (CID) in dogs at the Mandalay Bay Resort and Casino in Las Vegas on Sunday, March 6, 2022 from 5:30 PM - 7:30 PM Pacific Time during the Western Veterinary Conference (WVC), which is being held at the same location. Noted veterinary oncologist Dr. Craig A.

Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas

In December of 2021, FDA conditionally approved Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under the name Canalevia™-CA2, for treatment of EID in dogs SAN FRANCISCO, CA / ACCESSWIRE / February 16, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has submitted a request to the U.S. Food and Drug Administration's Center for Veterinary Medicine for Minor Use/Minor Species (MUMS) designation for the company's oral plant-based drug candidate Canalevia™ (crofelemer) for treatment of exercise-induced diarrhea (EID) in dogs. "MUMS designation is a status similar to ‘orphan drug' status for human drugs, and it makes the proposed intended use of a MUMS drug eligible for specific incentives supporting product approval or conditional approval.

Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs

SME status is an important designation for Italy-based Napo Therapeutics' rare/orphan disease business model SAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / February 15, 2022 / Jaguar Health (NASDAQ:JAGX) and Napo Therapeutics S.p.A., an Italian corporation established by Jaguar Health in Milan, Italy, today announced that Napo Therapeutics has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA).

Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency

Canalevia™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has completed filing of the final major regulatory section with the U.S. Food and Drug Administration's ("FDA") Center for Veterinary Medicine (CVM) to support conditional new animal drug approval of the company's oral plant-based drug candidate Canalevia (crofelemer delayed-release tablets) to treat exercise-induced diarrhea (EID) in dogs. In December of 2021, Jaguar Animal Health received conditional approval from the FDA for Canalevia™-CA1 for chemotherapy-induced diarrhea (CID) in dogs.

Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs

Study results expected to be described in upcoming presentations and publications CDD patients face intestinal failure (IF), similar to patients suffering from short bowel syndrome (SBS) - the priority focus for ODD development for crofelemer SAN FRANCISCO, CA / ACCESSWIRE / February 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) and Napo Pharmaceuticals, the company's wholly owned subsidiary, today announced the completion of a third-party, investigator-initiated preclinical enterocyte (intestinal cell) in vitro study to evaluate the effects of crofelemer,Napo Pharmaceuticals' plant-based prescription drug, on certain genetic defects that result in specific forms of congenital diarrheal disorders. Jaguar Health believes that these study results will support certain requests received from the Office of Orphan Products Development at the U.S. Food and Drug Administration (FDA) in response to the Orphan Drug Designation (ODD) application Napo Pharmaceuticals filed with the FDA for crofelemer for congenital diarrheal disorders (CDD) in infants and children.

Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)

Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (SBS) For SBS, Napo Therapeutics has been granted Orphan-Drug Designation for crofelemer by the European Medicines Agency, and Jaguar Health has been granted Orphan-Drug Designation for crofelemer by the FDA SAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / January 24, 2022 / Jaguar Health (NASDAQ:JAGX) and Napo Therapeutics S.p.A., an Italian corporation established by Jaguar Health in Italy, today announced the appointment of Martire Particco, MD, a physician with 30+ years of experience in Europe's pharmaceutical industry and in clinical practice, as Chief Medical Officer of Napo Therapeutics.

Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics

2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure (SBS-IF) and received conditional approval for Canalevia™-CA1 (crofelemer) for dogs Pipeline advancing in 2022 with company's Phase 3 CTD study continuing and expected completion of an SBS-IF investigator-initiated proof-of-concept trial 2022: Jaguar's year of the dog with continued launch, education, and promotion activity for Canalevia-CA1, which received conditional approval December 21, 2021, for chemotherapy induced diarrhea in dogs SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today provided a corporate update and outlined expected 2022 milestones. "2021 was a year of progress for Jaguar Health as we advanced our key human pipeline initiatives with the presentation at December's San Antonio Breast Cancer Symposium of Phase 2 data for prophylaxis in chemotherapy-related diarrhea; received Orphan Drug Designation in the European Union for crofelemer for short bowel syndrome; formed Napo Therapeutics in Milan, Italy, which was subsequently funded as a result of the merger of Napo Therapeutics with Milan-based Dragon SPAC S.p.A.

Jaguar Health Provides Corporate Update and Outlines 2022 Milestones

China Rapid Finance

Zomedica

Check these three under $1 penny stocks out for your watchlist The post 3 Penny Stocks to Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch Under $1 Right Now

Jaguar Health Inc (NASDAQ:JAGX) shares are trading higher following a Tuesday 13G filing from Oasis Capital showing a 9.99% stake in the company. According to the filing, Oasis Capital has a passive stake of 4,604,484 shares in Jaguar Health.

Why Jaguar Health Shares Are Rising

JAGX stock is rallying on Wednesday after a rough year thanks to news that Oasis Capital has taken a 10% stake in Jaguar Health. The post JAGX Stock Alert: What Is Going on With Jaguar Health Today?

JAGX Stock Alert: What Is Going on With Jaguar Health Today?

Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from FDA U.S. veterinarians, veterinary oncologists, and members of the media can click here to register for the CID Treatment Forum; Remote access will be available to participants unable to attend in person SAN FRANCISCO, CA / ACCESSWIRE / January 12, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company is hosting a treatment forum for veterinarians about chemotherapy-induced diarrhea (CID) in dogs on Sunday, January 16 from 6 p.m. - 8 p.m. Eastern during the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida.

Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida

The Canalevia.com website, a resource for veterinarians and dog owners, is now live Canalevia™-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / January 4, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the launch of Canalevia™-CA1 (crofelemer delayed-release tablets), Jaguar's plant-based prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 received conditional approval from the FDA on December 21, 2021.

Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / December 22, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today shared the following quote from the press release the U.S. Food and Drug Administration (FDA) issued December 21, 2021: "Diarrhea is a common side effect of chemotherapy in dogs, which can be so severe that cancer treatment must be halted. Chemotherapy drugs often have potential side effects, but, unlike in human medicine where patients may be willing to tolerate some discomfort in exchange for a potential cure, the primary purpose of cancer treatment in dogs and other pets is to extend survival without sacrificing quality of life and comfort," said Steven M.

Jaguar Health Shares Comments from FDA's December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs

The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by 20% in the most recent trading session. This is why it happened.

Jaguar Health Stock (JAGX): Why The Price Surged

The FDA has granted conditional approval for Jaguar Health Inc's (NASDAQ: JAGX) Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced diarrhea (CID) in dogs. This is the first and only product indicated for treating chemotherapy-induced diarrhea (CID) in dogs to receive any approval from the FDA.

FDA Approves Jaguar Health's Plant-Based Therapy For Chemo-Induced Diarrhea In Dogs

Shares of JAGX stock are flying higher after the FDA granted conditional approval for its chemotherapy-induced diarrhea treatment. The post JAGX Stock Alert: 5 Things to Know About the News Sending Jaguar Health Higher appeared first on InvestorPlace.

JAGX Stock Alert: 5 Things to Know About the News Sending Jaguar Health Higher

By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / December 21, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced it received conditional approval to market Canalevia™-CA1 (crofelemer delayed-release tablets), Jaguar's oral plant-based prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. This is the first and only product indicated for the treatment of chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from FDA.

Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA

Galera Therapeutics

Petros Pharmaceuticals

Which penny stocks are you watching right now? The post Trending Penny Stocks to Buy Today?

Trending Penny Stocks to Buy Today? 3 For Your Watchlist

SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the name of its majority owned subsidiary changed from Napo EU S.p.A. to Napo Therapeutics S.p.A.

Jaguar Health's Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company's Focus on Rare Diseases & Orphan Drugs

The recognition of Orphan Drug Designation in Europe for crofelemer for this rare disease is the first key milestone of Napo EU under the company's exclusive license agreement with Jaguar Health SAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / December 13, 2021 / Jaguar Health (NASDAQ:JAGX) and its majority owned Italian subsidiary, Napo EU S.p.A. (soon to be renamed Napo Therapeutics), today announced that the European Commission has adopted the decision to grant Orphan Drug Designation (ODD) for crofelemer for the indication of short bowel syndrome (SBS) in the European Union following review of the ODD application Napo EU submitted to the European Medicines Agency (EMA) this past September.

European Medicines Agency Grants Orphan Drug Designation for Crofelemer to Napo EU, Jaguar Health's Italian Subsidiary, for Short Bowel Syndrome

Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients SAN FRANCISCO, CA / ACCESSWIRE / December 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) and its wholly owned subsidiary Napo Pharmaceuticals today announced the third-party presentation of findings from the investigator-initiated HALT-D trial evaluating crofelemer for preventing chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane. These therapies cause CID in up to 80% of breast cancer patients, reaching grade 3, which often requires hospitalization, in 8-12% of patients.

Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)

News for Jaguar Health Stock (JAGX)